

A/902 Seg

Docket Number		4-31664A/USN	
<b><u>FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10</u></b>			
<u>EL913013965US</u> Express Mail Label Number		<u>December 19, 2001</u> Date of Deposit	

Address to: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

U.S. PTO. 979,913

9/9 U.S. F  
10/024935

12/19/01

## UTILITY PATENT APPLICATION TRANSMITTAL AND FEE SHEET

Transmitted herewith for filing under 37 CFR §1.53(b) is the utility patent application of

Applicant (or identifier): BAIR ET AL.

Title: INHIBITORS OF THE E2F-1/CYCLIN INTERACTION FOR CANCER THERAPY

Enclosed are:

1. ☒ Specification (Including Claims and Abstract) - 37 pages
2. ☐ Drawings - sheets
3. ☒ Unexecuted Declaration and Power of Attorney (original or copy)
4. ☐ Microfiche Computer Program (appendix)
5. ☐ Nucleotide and/or Amino Acid Sequence Submission
  - ☒ Computer Readable Copy
  - ☒ Paper Copy
  - ☐ Statement Verifying Identity of Above Copies
6. ☐ Preliminary Amendment
7. ☐ Assignment Papers (Cover Sheet & Document(s))
8. ☐ English Translation of
9. ☐ Information Disclosure Statement
10. ☐ Certified Copy of Priority Document(s)
11. ☒ Return Receipt Postcard
12. ☒ Other: Application Data Sheet

Filing fee calculation:

- ☐ Before calculating the filing fee, please enter the enclosed Preliminary Amendment.  
☐ Before calculating the filing fee, please cancel claims .

Basic Filing Fee								\$	740
Multiple Dependent Claim Fee (\$ 280)								\$	
Foreign Language Surcharge (\$ 900)								\$	
	For	Number Filed		Number Extra		Rate			
Extra Claims	Total Claims	10	-20	0	x	\$	18	= \$	
	Independent Claims	1	-3	0	x	\$	84	= \$	
TOTAL FILING FEE								\$	740


- ☒ Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$740. An additional copy of this paper is enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.16 and §1.17 which may be required in connection with this application, or credit any overpayment, to Deposit Account No. 19-0134 in the name of Novartis Corporation.

Please address all correspondence to the address associated with Customer No. 001095, which is currently:

Thomas Hoxie  
Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027

Please direct all telephone calls to the undersigned at the number given below, and all telefaxes to (908) 522-6955.

Respectfully submitted,

  
Hesna J. Pfeffer  
Attorney for Applicants  
Reg. No. 22,640  
Tel. No. (908) 522-6940

Date: December 19, 2001